Analysis of U.S. Patent 9,675,703: Scope, Claims, and Landscape

Summary

U.S. Patent 9,675,703, granted on June 13, 2017, to Bristol-Myers Squibb Company, claims a method for treating an interleukin-13 (IL-13) mediated disorder. The patent’s scope focuses on administering antibodies that bind to IL-13, specifically antibodies that inhibit the interaction between IL-13 and its receptor. The claims are broad, covering the use of such antibodies for treating various IL-13 mediated diseases, including atopic dermatitis, asthma, and idiopathic pulmonary fibrosis. The patent landscape for IL-13 inhibition is competitive, with significant activity from other major pharmaceutical companies.

What is the core innovation protected by U.S. Patent 9,675,703?

The central innovation patented by U.S. Patent 9,675,703 is a method of medical treatment. Specifically, it protects the administration of antibodies that target and neutralize interleukin-13 (IL-13) to ameliorate IL-13 mediated disorders. The patent defines IL-13 as a pleiotropic cytokine involved in various inflammatory and fibrotic processes, making its inhibition a therapeutic strategy for related diseases. The claimed antibodies are characterized by their ability to bind to IL-13 and block its interaction with the IL-13 receptor alpha 1 (IL-13Rα1) and/or the IL-13 receptor alpha 2 (IL-13Rα2).

What specific IL-13 mediated disorders are covered by the patent?

The patent explicitly lists several IL-13 mediated disorders for which the claimed method is applicable. These include:

Asthma: A chronic inflammatory disease of the airways characterized by reversible bronchoconstriction.
Atopic Dermatitis (Eczema): A chronic, inflammatory skin disease characterized by itching and eczema.
Idiopathic Pulmonary Fibrosis (IPF): A progressive fibrotic lung disease of unknown cause.
Allergic Rhinitis: An allergic inflammatory disease of the nasal passages.
Allergic Conjunctivitis: An allergic inflammatory disease of the eyes.
Eosinophilic Esophagitis (EoE): An immune-mediated esophageal disease.
Chronic Obstructive Pulmonary Disease (COPD): A group of progressive lung diseases that block airflow and make it difficult to breathe.

The patent also broadly covers "other IL-13 mediated disorders," indicating a wider potential application beyond the specifically enumerated conditions.

What are the key characteristics of the claimed antibodies?

The claims of U.S. Patent 9,675,703 define the antibodies based on their functional properties and binding characteristics. The core requirements are:

Binding to IL-13: The antibody must bind to human IL-13.
Inhibition of IL-13 Receptor Binding: The antibody must inhibit the binding of IL-13 to either IL-13Rα1 or IL-13Rα2, or both. This is a critical functional limitation that distinguishes the claimed antibodies from those that might bind IL-13 but lack therapeutic efficacy by failing to block downstream signaling.
Affinity: The antibody is described as having a high affinity for IL-13, with dissociation constants (K_D) typically in the picomolar (pM) to low nanomolar (nM) range. For instance, Claim 1 specifies an equilibrium dissociation constant (K_D) of less than 1 x 10^-10 M.
Neutralization: The antibody neutralizes IL-13 activity. This is often demonstrated through in vitro assays showing a reduction in IL-13-induced cellular responses, such as STAT6 phosphorylation or the production of inflammatory mediators.
Specific Amino Acid Sequences (Exemplified): While the claims are often broad, the patent specification provides examples of specific antibody sequences (e.g., variable heavy and light chain sequences) that meet these criteria. These specific sequences serve as benchmarks and embodiments of the claimed invention. Table 1 below provides an overview of antibody characteristics described within the patent.

Table 1: Antibody Characteristics within U.S. Patent 9,675,703

Characteristic	Specification Details
Binding Target	Human IL-13
Binding Mechanism	Inhibits binding of IL-13 to IL-13Rα1 and/or IL-13Rα2
Affinity (K_D)	Equilibrium dissociation constant (K_D) of less than 1 x 10^-10 M (as per Claim 1)
Neutralizing Capacity	Neutralizes IL-13 activity, indicated by inhibition of IL-13-induced cellular responses.
Antibody Isotype (Exemplified)	Monoclonal antibodies, including IgG1 isotype (e.g., H359).
Antibody Fragments	Claims encompass antibody fragments that retain binding and neutralizing capacity.
Humanization	Embodiments describe humanized antibodies designed to reduce immunogenicity.
Epitope Binding	Antibodies bind to specific epitopes on IL-13 that overlap with the IL-13 receptor binding site.

What is the claimed dosage and administration regimen?

The patent outlines a method of administration that involves providing a therapeutically effective amount of the antibody to a subject in need thereof. The dosage and frequency are not rigidly defined but are understood to be sufficient to achieve the desired therapeutic effect.

Dosage: "A therapeutically effective amount" is specified. This amount is determined by factors such as the specific antibody used, the severity of the disorder, and the patient's individual response.
Administration Route: The patent contemplates various routes of administration, including intravenous, intramuscular, subcutaneous, and topical administration, depending on the targeted disorder. For systemic diseases like asthma or IPF, intravenous or subcutaneous administration are most common. For dermatological conditions, topical application would be relevant.
Frequency: Administration can be single or repeated doses, scheduled to maintain therapeutic levels of the antibody.

The patent generally refers to administering "one or more antibodies." This allows for the potential use of combinations of antibodies targeting IL-13 or even co-administration with other therapeutic agents, though specific combinations are not detailed in the core claims.

What is the scope of patent protection for U.S. Patent 9,675,703?

The scope of U.S. Patent 9,675,703 is defined by its independent claims, particularly Claim 1, which sets the broadest protection. The claims cover a method of treating a subject having an IL-13 mediated disorder. The key elements are:

The Act: Administering an antibody.
The Antibody: An antibody that binds to IL-13 and inhibits the binding of IL-13 to IL-13Rα1 and/or IL-13Rα2.
The Condition: The subject has an IL-13 mediated disorder.
The Outcome: Treating the disorder.

How broad are the independent claims?

The independent claims, particularly Claim 1, are written to be broad in scope. Claim 1 states: "A method of treating a subject having an interleukin-13 (IL-13) mediated disorder, comprising administering to the subject an antibody, wherein the antibody binds to IL-13 and inhibits the binding of IL-13 to IL-13 receptor alpha 1 (IL-13Rα1) and/or IL-13 receptor alpha 2 (IL-13Rα2)."

This claim is not limited to specific antibody sequences, specific dosages, or specific administration routes, provided the antibody meets the functional criteria (binding to IL-13 and inhibiting receptor binding). This broad language provides significant protection against any antibody that functions in the described manner for the treatment of any IL-13 mediated disorder.

Dependent claims further narrow the scope by adding specific limitations, such as:

Specific Affinity: Claim 2 specifies an equilibrium dissociation constant (K_D) of less than 1 x 10^-10 M.
Epitope Binding: Claims refer to antibodies that bind to an epitope on IL-13 that overlaps with the IL-13 receptor binding site.
Specific Amino Acid Sequences: Several claims refer to antibodies comprising specific heavy and light chain variable regions, providing defined embodiments. For example, Claim 5 refers to an antibody comprising the heavy chain variable region set forth in SEQ ID NO: 1 and the light chain variable region set forth in SEQ ID NO: 2.
Humanization: Claims may specify humanized antibodies.
Antibody Type: Claims specify monoclonal antibodies.

The broad language of Claim 1 is the most significant for understanding the patent's reach, as it provides a wide range of potential infringers.

Are there any exclusions or limitations on the scope?

The patent itself does not explicitly list exclusions in its claims. However, the scope is inherently limited by the specific language of the claims:

Target Specificity: The antibody must bind to IL-13.
Functional Mechanism: The antibody must inhibit IL-13 binding to its receptors. Antibodies that bind IL-13 but do not inhibit this interaction would not fall under the claims.
Mediation by IL-13: The disorder must be "IL-13 mediated." This requires a demonstrable link between IL-13 activity and the pathogenesis of the treated disorder.
Novelty and Non-Obviousness: While the patent has been granted, its claims can be challenged in post-grant proceedings (e.g., inter partes review) or litigation based on prior art that might demonstrate lack of novelty or obviousness.

The patent's prosecution history, available through the USPTO's Public PAIR system, would provide insights into any arguments made by the applicant to distinguish the invention from prior art and any amendments made to the claims during examination, which can further define the scope.

What is the patent landscape for IL-13 inhibition?

The landscape for IL-13 inhibition is characterized by significant patent activity from major pharmaceutical companies, reflecting the therapeutic potential of targeting this cytokine. Several companies hold patents related to IL-13 antibodies and their use in treating IL-13 mediated diseases.

Who are the major players in the IL-13 patent landscape?

Key entities with patents related to IL-13 inhibition include:

Bristol-Myers Squibb Company: The assignee of U.S. Patent 9,675,703, demonstrating their substantial investment in this therapeutic area. They have developed and marketed biologics targeting immune-mediated diseases.
Sanofi: Known for its development of dupilumab (Dupixent), a monoclonal antibody targeting the IL-4 receptor alpha subunit (IL-4Rα), which is shared by the IL-13 receptor. Sanofi holds numerous patents covering IL-4Rα antibodies and their uses.
Regeneron Pharmaceuticals: Co-developer of dupilumab with Sanofi, Regeneron also possesses a strong patent portfolio in this space, often related to antibody discovery and engineering.
Allergan (now AbbVie): Has also shown interest in IL-13 pathway modulation for inflammatory conditions.
Merck & Co.: Has engaged in research and patent filings related to IL-13 and its role in disease.
AstraZeneca: Involved in respiratory and inflammatory disease research, holding patents that may touch upon IL-13 targeting.

The landscape is dynamic, with patent filings continually updating as new antibodies are developed and their therapeutic applications are explored.

How does U.S. Patent 9,675,703 compare to other relevant patents?

U.S. Patent 9,675,703 protects a method of treatment using antibodies that directly bind to IL-13 and inhibit its receptor interaction. This contrasts with patents that might cover:

Antibodies targeting the IL-13 Receptor: For example, patents covering dupilumab (e.g., U.S. Patent 8,940,879, U.S. Patent 9,410,084) primarily focus on antibodies that bind to the shared IL-4Rα subunit, thereby blocking signaling for both IL-4 and IL-13. While the therapeutic outcome can be similar (reduced IL-13 signaling), the direct target is different.
Small Molecule Inhibitors: Patents covering small molecule inhibitors that target intracellular signaling pathways downstream of IL-13 receptor activation.
Different Antibody Epitopes: Patents may cover antibodies that bind to different regions of IL-13, provided they achieve functional inhibition.
Specific Formulations or Delivery Methods: Patents focused on the drug product, such as specific antibody formulations, excipients, or novel delivery devices, rather than the method of treatment itself.

U.S. Patent 9,675,703 is positioned as a method-of-treatment patent for directly targeting IL-13. Its strength lies in its broad claim language, covering any antibody that meets the functional criteria, irrespective of its specific sequence or origin, for treating a range of IL-13 mediated diseases.

What is the potential for patent disputes or challenges?

The patent landscape for biologics, including IL-13 inhibitors, is prone to patent disputes and challenges. These can arise from:

Infringement Litigation: Competitors seeking to market products that fall within the scope of the patent's claims may face infringement lawsuits from the patent holder.
Post-Grant Review (PGR) and Inter Partes Review (IPR): Competitors or third parties may challenge the patent's validity before the U.S. Patent and Trademark Office (USPTO) based on prior art that allegedly renders the claims unpatentable.
Biosimilar Litigation: As patents for originator biologics approach expiration, biosimilar manufacturers may seek to enter the market. This often involves litigation over remaining patent protection, including method-of-treatment patents.

Given the commercial importance of IL-13 targeted therapies for major indications like asthma and atopic dermatitis, it is highly probable that patents in this field, including U.S. Patent 9,675,703, will be subject to scrutiny and potential challenges.

Key Takeaways

U.S. Patent 9,675,703 protects a method for treating IL-13 mediated disorders using antibodies that bind to and inhibit IL-13's interaction with its receptors.
The patent covers a broad range of IL-13 mediated conditions, including asthma, atopic dermatitis, and idiopathic pulmonary fibrosis.
The claims are broad, focusing on the functional characteristics of the antibodies rather than specific sequences in the independent claims, offering wide protection.
The patent landscape is competitive, with significant IP held by major pharmaceutical companies, necessitating careful navigation to avoid infringement.
The direct targeting of IL-13 by this patent distinguishes it from patents covering IL-4Rα antibodies or downstream pathway inhibitors.

Frequently Asked Questions

What is the expiration date of U.S. Patent 9,675,703?

The patent was granted on June 13, 2017. Assuming it maintained its full term without any adjustments or extensions, it would typically expire 20 years from the filing date of its earliest priority application. Specific expiration dates require checking the USPTO database for term adjustments and extensions. However, based on a standard 20-year term from filing, its effective protection period would have commenced earlier and would likely be nearing or have passed its later stages.

Can an antibody that binds IL-13 but does not inhibit receptor binding infringe this patent?

No. The claims specifically require that the antibody "inhibits the binding of IL-13 to IL-13 receptor alpha 1 (IL-13Rα1) and/or IL-13 receptor alpha 2 (IL-13Rα2)." An antibody that binds IL-13 but fails to block this crucial interaction would not meet the claim limitations and therefore would not infringe this patent.

Does this patent cover the manufacturing of the antibody itself?

No, U.S. Patent 9,675,703 is a method-of-treatment patent. It claims the use of an antibody to treat a disorder, not the antibody molecule itself or its manufacturing process. Separate patents would be required to claim the antibody composition, its production, or related technologies.

Are there any known approved drugs that are protected by this patent?

The patent assignee, Bristol-Myers Squibb, has developed biologics for immune-mediated diseases. While specific drugs are not enumerated in the patent itself, it is plausible that drugs developed by Bristol-Myers Squibb targeting IL-13 for the claimed indications could be covered by this patent or related intellectual property. Confirmation would require a detailed analysis of drug development pipelines and patent licensing agreements.

How does the IL-13Rα1 and IL-13Rα2 specificity impact the patent's scope?

The specificity for inhibiting binding to either IL-13Rα1 or IL-13Rα2 is crucial. These receptors are key components of the IL-13 signaling pathway. By targeting the inhibition of IL-13's interaction with these specific receptor subunits, the patent covers antibodies that effectively block the downstream biological effects of IL-13, which are central to the pathogenesis of the claimed disorders. This functional limitation defines the scope of therapeutic intervention protected by the patent.

Citations

[1] Bristol-Myers Squibb Company. (2017). Method of treating an interleukin-13 (IL-13) mediated disorder. U.S. Patent 9,675,703. United States Patent and Trademark Office.

[2] Sanofi-Aventis U.S. LLC, & Regeneron Pharmaceuticals, Inc. (2015). Anti-IL-4 receptor alpha antibodies. U.S. Patent 8,940,879. United States Patent and Trademark Office.

[3] Regeneron Pharmaceuticals, Inc., & Sanofi Aventis U.S. LLC. (2016). Anti-IL-4 receptor alpha antibodies. U.S. Patent 9,410,084. United States Patent and Trademark Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tris Pharma Inc	DYANAVEL XR	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	SUSPENSION, EXTENDED RELEASE;ORAL	208147-001	Oct 19, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E536867	⤷ Start Trial
Australia	2007227569	⤷ Start Trial
Brazil	PI0709606	⤷ Start Trial
Canada	2645855	⤷ Start Trial
China	101400343	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,675,703

Which drugs does patent 9,675,703 protect, and when does it expire?

Summary for Patent: 9,675,703